The tablet is expected to be used in the context of a clinical trial for treatment of impairments in cognitive functioning (including mild cognitive impairment that could result
Soft Tissue Sarcoma (STS) affects approximately 2.8 in 10,000 people in the EU and a recent statistic estimated 5-year survival rate of 58 % for patients suffering from
PharmaMar submitted the above mentioned application for the antitumor drug of marine origin, Aplidin, in combination with dexamethasone given the positive results obtained from the ADMYRE study. Plitidepsin
Study 311 is a global multicenter, single-arm Phase III clinical study of perampanel in approximately 160 patients (ages 4 to less than 12 years) with inadequately controlled partial-onset
Investors participating in the round included VI Partners via the Venture Incubator fund and Zürcher Kantonalbank. The proceeds will be used to progress a drug candidate from Inositec’s
The study met its primary endpoint in this cohort as measured by a change in total chloride response following 4 weeks of treatment with QR-010. In the compound
In April 2015, the FDA granted orphan drug status to ADS-5102 for this indication. Adamas Pharmaceuticals chairman and CEO Gregory Went said: "The ADS-5102 NDA submission represents a major milestone
Patients who received apatorsen treatment experienced a 20% reduction in risk of death, compared to patients receiving docetaxel alone (HR=.80; 95% CI: 0.65-0.98; p=0.078). The primary analysis was
Professor Eicke Latz, Director of the Institute, and Professor Matthias Geyer, Department Head for Structural Immunology, are scientific Co-founders of IFM Therapeutics. IFM Therapeutics’ scientific mission is to
The portfolio is a mix of filed ANDAs pending approval by the US Food and Drug Administration (USFDA) and ANDAs that will be filed imminently, and comprised of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.